Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
Chemotherapy treatment of malignancy accounts for 1–2% of takotsubo syndrome (TS) triggers. Women comprise 60–70% of patients with chemotherapy-associated TS, a distinctly lower prevalence than the 90% female prevalence in TS overall. Fluorouracil is the most commonly reported TS-triggering chemothe...
Guardado en:
| Autores principales: | Katelyn Storey, Scott W Sharkey |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Radcliffe Medical Media
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2ca97b83a2134bdabf38af4fc13a2ed4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Diagnosis of Takotsubo syndrome in the COVID-19 era
por: Kristian Rivera, et al.
Publicado: (2021) -
Diagnosis of Takotsubo syndrome in the COVID-19 era
por: Kristian Rivera, et al.
Publicado: (2021) -
Novel Aspects of Classification, Prognosis and Therapy in Takotsubo Syndrome
por: Chiara Di Filippo, et al.
Publicado: (2019) -
Takotsubo Syndrome During the COVID-19 Pandemic: State-of-the-Art Review
por: Gassan Moady, MD, et al.
Publicado: (2021) -
Takotsubo syndrome early after treatment due to non cardiotoxic chemotherapy agents
por: Benay Özbay, et al.
Publicado: (2021)